Xenitra Limited’s Q3 sales soared to $8.3 million, a 300% jump over Q2, driven by its Nutritionals division and a strategic $30 million partnership with Rockcheck Group for Danone products. The company also launched new OTC medicines and blockchain tokenised sales channels poised to fuel future growth.
